Genprex expands gene therapy manufacturing

By The Science Advisory Board staff writers

June 16, 2020 -- Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.

Under the agreement, Aldevron will produce TUSC2 plasmid DNA, the active ingredient for the Genprex's lead immunogene therapy candidate, Oncoprex. The commercial-scale manufacturing efforts will enable Genprex to significantly lower costs per unit of product manufactured.

The manufactured TUSC2 plasmid DNA will be encapsulated with a lipid nanoparticle to form Oncoprex. According to preclinical data, the drug should induce cell signaling that triggers programmed cell death and modulation of the immune system when transfected into cancer cells.

Genprex's upcoming phase I/II clinical trial of Oncoprex will be combined with osimertinib for non-small cell lung cancer (NSCLC). Osimertinib, which is marketed by AstraZeneca as Tagrisso, received fast track designation in January and the trial is expected to be started in early 2021. A combination trial with Oncoprex and Keytruda in NSCLC is also planned for the near future.

Kite to manufacture CAR T-cell therapy in Europe
Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European...
Sexton, BioSpherix collaborate to support cell & gene therapy needs
Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.
Egle, Takeda collaborate on anti-Treg immunotherapies
Egle Therapeutics has formed a strategic research alliance with Takeda Pharmaceutical to validate novel regulatory T-cell (Treg) targets, against which...
Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...

Copyright © 2020 scienceboard.net


Conferences
Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter